Here are the key takeaways from the full Times Magazine story about the F.D.A.: The F.D.A.’s regulators have an enormous ...

Jeneen Interlandi, a domestic correspondent for Opinion and a staff writer at the magazine, writes frequently about public health. For this article, she interviewed dozens of people who have worked ...

Investors have long asked the FDA to share its reasons for rejecting drugs, arguing that companies can use the agency’s silence on the matter to mislead the market.

Beyond staff cuts, the departures of some longtime investigators in recent months have left less experienced people tasked ...

Unlike Drs. Adam Cifu and John Mandrola, I do not constantly boast of my "nuance" or claim to be a master of "clinical appraisal." They have so much to teach me.

A new indication for omalizumab is prompting clinicians to adjust their approach to oral food challenges, but experts ...

Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX ...